Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tianyin Granted Two SFDA Approvals

publication date: Aug 14, 2009

Tianyin Pharmaceutical Co. received SFDA approvals for two new products: 0.5 gram/tablet formulations of Sanqi Tablets and Yinqiao Jiedu Tablets. Sanqi is a generic TCM that treats traumatic injuries and stops bleeding without causing blood stasis, while alleviating pain and reducing swelling. Also a generic TCM, Yinqiao Jiedu is used to treat acute respiratory system ailments, such as influenza and the common cold. More details...

Stock Symbol: (NYSE AMEX: TPI)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital